Broom Colin MD 4
4 · Nabriva Therapeutics plc · Filed Aug 21, 2019
Insider Transaction Report
Form 4
Broom Colin MD
Chief Executive Officer
Transactions
- Tax Payment
Ordinary Shares
2019-08-21$2.07/sh−10,177$21,066→ 125,724 total - Exercise/Conversion
Ordinary Shares
2019-08-19+33,750→ 135,901 total - Exercise/Conversion
Restricted Share Units
2019-08-19−33,750→ 33,750 total→ Ordinary Shares (33,750 underlying)
Footnotes (2)
- [F1]The restricted share units convert into ordinary shares on a one-for-one basis upon vesting of the units.
- [F2]On January 31, 2018, Nabriva Therapeutics plc (the "Issuer") granted the reporting person 67,500 restricted share units ("RSUs"). Fifty percent (50%) of the RSUs vested on August 19, 2019 upon certifcation by the board of directors of the Issuer of the receipt by the Issuer of approval of a new drug application by the U.S. Food and Drug Administration for lefamulin (the "Performance Condition"), and the remaining fifty percent (50%) of the RSUs will vest on the one (1) year anniversary of the Performance Condition.